Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA in Talks for 3 Potential Deals w/ Potential Upfront Payments/ Others ~US$5B in Total
Recommend 17 Positive 28 Negative 16 |
||||
|
||||
|
CSPC PHARMA (01093.HK) is currently in negotiations with certain independent third parties regarding three potential transactions involving license and collaboration in relation to the development, manufacturing and commercialization of certain products of the Group, including epidermal growth factor receptor antibody drug conjugate (EGFR-ADC) and other pharmaceutical products developed under the Group's technology platforms, according to CSPC PHARMA's announcement. The potential upfront payments, potential development milestone payments, potential commercialization milestone payments that may be payable to the Group under each of the potential transactions may amount to approx. US$5 billion in aggregate. One of the three potential transactions is at an advanced stage and is currently expected to be finalized in June. Currently, the terms and conditions of the potential transactions are yet to be finalized and no definitive agreement has been entered into by the Group regarding the potential transactions. As such, the potential transactions may or may not proceed. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
